Immunomodulator
US11123324B2 · kind B2 · utility
0Cited by
2References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 17, 2017 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Aug 17, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.